Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues

~ First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery ~ No venous ulcer recurrences or CVI relapses ~ Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here